FDG-PET预测转移性黑色素瘤抗PD-1治疗的长期结局
该回顾性分析纳入104例转移性黑色素瘤患者,基线及1年时行PET和CT,用RECIST和EORTC标准评估1年反应,从1年landmark计算PFS和OS。中位随访61个月,5年时94%存活,PET完全代谢反应(CMR)者5年PFS率90%,非CMR者54%,PET较CT更好地预测进展。
要点
- 1年PET CMR者5年PFS率90%,非CMR者54%,PET预测进展优于CT。
- CT部分缓解(PR)者中,CMR者5年PFS率88%,非CMR者59%。
- 5年OS率在CR与PR/SD(100% vs 91%)及CMR与非CMR(96% vs 87%)间均优异。
核心结论
- 1年PET后5年,多数患者维持缓解,尤其CMR者,PET较CT更好预测进展,少数进展者多为孤立病灶且局部处理后OS仍优异。
研究设计与样本
- 回顾性分析104例转移性黑色素瘤患者,均有基线及1年PET和CT,1年反应分别用RECIST(CT)和EORTC标准(PET)判定,从1年landmark计算PFS和OS。
主要发现
- 中位随访61个月(范围58-64个月),94%存活,除1例外均在治疗中位23个月(范围1-59个月)后停药。
- 19例(18%)出现疾病进展,其中10例(53%)在治疗中,12例(63%)为孤立部位,8例(67%)接受局部治疗。
- PET后5年RECIST PFS率:CR vs PR/SD为93% vs 76%,CMR vs 非CMR为90% vs 54%;PR患者中CMR vs 非CMR为88% vs 59%。
- 35例(34%)在12个月内停药(CR中14/29,CMR中31/78),多因毒性,与继续治疗者PFS率相比无影响(84% vs 78%)。
- 5年OS率:CR vs PR/SD为100% vs 91%,CMR vs 非CMR为96% vs 87%。
临床怎么用
- FDG-PET可用于评估CT残留病灶并预测长期获益,1年CMR者预后良好。
局限性
- 回顾性分析,样本量104例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We have previously shown that 75% of patients treated with programmed cell death protein 1 (PD-1) with or without CTLA4 who have not progressed by 1 year have complete metabolic response (CMR), including two-thirds of patients with partial response (PR). We now report 5-year outcomes. PATIENTS AND METHODS: Retrospective analysis of 104 patients with baseline and 1-year positron emission tomography (PET) and computed tomography (CT). The 1-year response was determined using RECIST for CT and European Organisation for Research and Treatment of Cancer (EORTC) criteria for PET. Progression-free survival (PFS) and overall survival (OS) were determined from the 1-year landmark. RESULTS: At the median follow-up of 61 months (range 58-64 months) from 1-year PET, 94% remained alive and all but one had discontinued treatment after a median treatment duration of 23 months (range 1-59 months). Disease progression occurred in 19 patients (18%): 10 (53%) while on treatment and 12 (63%) in solitary sites for which 8 (67%) received local treatment. RECIST PFS rate at 5 years after PET was higher in complete response (CR) compared with PR/stable disease (SD) (93% versus 76%, respectively) and CMR compared with non-CMR (90% versus 54%, respectively). In patients with PR, 5-year PFS rate was superior in CMR (88% and 59%). A total of 35 (34%) patients (14/29 in CR, 31/78 in CMR) discontinued treatment within 12 months, largely due to toxicity, with no impact on PFS rate compared with those that continued (84% versus 78%). Despite progression events, OS rate at 5 years was excellent and similar in patients with CR and PR/SD (100% versus 91%, respectively) as well as in those with CMR and non-CMR (96% versus 87%, respectively). CONCLUSIONS: Five years after the 1-year PET, sustained responses are observed in the majority of patients, particularly in those with CMR. PET continues to predict progression better than CT, particularly in those with residual disease on CT. In the minority that progress, often in solitary sites and managed locally, OS rate remains excellent. PET is effective in evaluating residual lesions on CT and can predict long-term benefit.
引用
- Dimitriou F, Lo SN, Tan AC, et al. FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma. Ann Oncol. 2021. PMID: 34687894. doi:10.1016/j.annonc.2021.10.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。